Adrenaline autoinjector supply disruption
In response to the ongoing supply disruption of adrenaline autoinjectors, MHRA has allowed an extension of the use of specific lot (batch) numbers of Jext 150 mcg and Jext 300 mcg auto-injectors beyond the labelled expiry date by 4 months. See Jext website for list of affected batches.
Advise patients to continue to check periodically the viewing window in the label of their autoinjector to ensure that the liquid inside is clear and colourless and replace if the liquid is discoloured.
See also the updated Department of Health and Social Care supply disruption alert (issued 15 October 2018) and NHS England Pharmacy and Dispensing Practice Q&A for adrenaline autoinjectors.
Please note during this period of reduced supply, expert clinical guidance is to use 25 kg as the cut-off for switching from 150 mcg to 300 mcg dosage for all devices. For two of the devices (Jext and Emerade), this will be an off-label change.
Epanutin (phenytoin) 30mg/5ml oral suspension supply disruption
All healthcare professionals who prescribe, dispense or administer Epanutin oral suspension should be aware of the recommendations of the Department of Health and Social Care Supply Disruption Alert for Epanutin (phenytoin) 30mg/5ml oral suspension. Different formulations of phenytoin are not interchangeable and careful management of switching and monitoring is required.
MHRA has approved the import of stock phenytoin oral suspension from Canada. This stock is considered an unlicensed preparation in the UK. See alert for important advice for prescribers and pharmacists.
In October 2018, the following other letters were sent to healthcare professionals:
Drug alerts and recalls
In October 2018, MHRA issued the following Alerts and recalls for drugs:
Article citation: Drug Safety Update volume 12, issue 4: November 2018: 5.
Published 14 November 2018